Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
NCT00040599
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Colorectal Cancer
Colon Cancer
Rectal Cancer
Colorectal Neoplasms
Colorectal Carcinoma
Colorectal Tumor
Interventions
DRUG:
hMN14 (labetuzumab)
Sponsor
Gilead Sciences